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MeMbers of the eGf receptor faMily in norMal and 
patholoGical epiderMis
Yves Poumay, Vanio Mitev1 
Cell and Tissue Laboratory, URPHYM, University of Namur (FUNDP), Belgium, 1Department of Biochem-
istry, Medical University, Sofia, Bulgaria
abstract
epidermal growth factor (eGf) and analogs bind to transmembrane receptors that exhibit 
tyrosine kinase activity in their cytoplasmic domain and which belong to the eGf receptor 
family. These growth factors and relevant receptors were named after initial identification 
of the functions of their founding members in the epidermis. however, since the eGf re-
ceptor was recognized as an oncogene, it has been mainly analyzed in cancer; the members 
of the receptor’s family were also found and characterized initially in tumors and can-
cer cells. the present article reviews mainly the expression and function of eGf receptor 
family members in normal epidermis, together with the expression and function of their 
respective ligands, and we extend the review to potential involvement of these systems in 
epidermal disease.
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introdUction
Deregulation of growth factors and protooncogenes 
expression and activation have been suspected to 
be potentially critical agents in the pathogenesis 
of complex skin diseases, including psoriasis and 
cancer, in which the program of normal epidermal 
proliferation and differentiation is altered.1-3 Mul-
tiple in vitro and in vivo experiments, including 
also the production of transgenic mice, have now 
demonstrated that growth factors and oncogene 
overexpression in keratinocytes result indeed in 
variable anomalies in epidermal cell proliferation 
and differentiation.4-7 More specifically, a large 
proportion of the reports addressing the role of 
growth factors in skin and published during the last 
fifteen years dealt with the epidermal growth factor 
(EGF), with its activity-related ligands [transforming 
growth factor-α (TGF-α), amphiregulin, heparin-
binding EGF, epiregulin], and with the so-called 
EGF receptor, the receptor originally identified by 
its specific affinity for EGF.8,9
The number of characterized EGF-related growth 
factors increased rapidly and the EGF receptor 
was found to be the first member of a family of 
growth factor receptors composed of four members 
(Fig. 1) and named the type 1 family of growth 
factor receptors.10 For years, except for the EGF 
receptor itself, the involvement of the other recep-
tors of this family has received very little atten-
tion by skin biologists. Most likely, this lack of 
interest was the result of a longstanding absence 
of identified ligands showing specificity for those 
receptors. The identification of such ligands in 1992 
led skin biology researchers to pay more attention 
to other members of the EGF receptor family as 
receptors involved in skin in general, and in the 
epidermis in particular.11,12 Data from our labs, but 
also from several other labs, have motivated the 
present short review in which we summarize the 
knowledge about EGF receptor family members 
that are of special interest for epidermal biology 
and pathology.
the eGf receptor (c-ERBB-1/her-1) is an 
iMportant epiderMal reGUlator
The EGF receptor, the founding member of the type 
1 family of growth factor10, is a transmembrane 
glycoprotein (170 kDa) exhibiting extracellular 
cysteine-rich regions with high affinity binding capac-
ity for EGF, a cytoplasmic domain with characteristic 
tyrosine kinase activity, and a carboxy-terminal tail 
with potent autophosphorylation docking sites for 
signal transduction proteins (phospholipase C-γ, 
phosphoinositol-3-kinase, Shc or Grb2). Also called 
c-erbB-1, due to the similarity of its gene with the 
v-erb gene of avian erythroblastosis virus, the EGF 
receptor is named in human tissues the Human EGF 
Receptor-1 (HER1). As a result of EGF binding to 
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HER1, receptor dimerization occurs and phosphory-
lation of at least five cytoplasmic tyrosine residues 
can be detected, thereby revealing activation of the 
kinase and production of downstream intracellular 
signaling.9,10,13,14 Receptor dimerization (Fig. 2) is 
a process largely utilized by transmembrane growth 
factor receptors which exhibit inducible cytoplasmic 
tyrosine kinase activity to transduce signal from the 
environment into the cell.15 TGF-α, amphiregulin, 
betacellulin, and several other proteins, in addition 
to EGF, bind to HER1, promoting dimerization 
and tyrosine kinase activation.8,14 Most of these 
EGF-like ligands are normally expressed in skin 
and their expressions have interestingly been found 
particularly elevated in psoriatic skin.8 
The signaling pathway induced by the EGF re-
ceptor and its ligands is of particular relevance in 
normal and pathological skin. The multiple effects 
produced by activation of the EGF receptor on the 
physiology of normal epidermal keratinocytes, as 
well as evidence for roles in human skin diseases, 
have already been widely illustrated before.1,8,9,13,16 
We emphasize here only a few data from cell cul-
ture, transgenic animals and pathological samples to 
illustrate cutaneous effects. in human keratinocyte 
cultures, the autocrine cell growth, i.e. cell growth in 
a chemically-defined medium free of any peptide17, 
requires EGF receptor occupancy18. These cultures 
when confluent initiate terminal differentiation, but 
a treatment of growth-arrested keratinocytes with 
EGF inhibits the expression of early differentiation 
markers, although EGF does not impede the loss of 
cell clonogenicity.19 These finding provide evidence 
for the crucial roles of the EGF receptor and the 
binding of its ligands in controlling the cellular 
physiology of keratinocytes. With the production 
of transgenic mice lacking the EGF receptor, re-
searchers have provided deeper insights into the 
critical role of this signaling pathway for epidermal 
cells in vivo.20,21 These studies have revealed that, 
amongst several other organ anomalies, offspring 
lacking the EGF receptor and surviving for several 
days after birth exhibited anomalies in the skin, 
particularly in epidermis and epidermal appendages. 
interestingly, the lack of EGF receptor expression 
in mice produced stronger effects than the lack of 
figure 1. Members of the Human EGF Receptor family and their ligands. The EGF receptor, also called HER1, 
exhibits an extracellular domain which binds several ligands (including EGF, HB-EGF, amphiregulin, epiregulin, 
β-cellulin and TGF-α), a transmembrane domain, and a cytoplasmic domain containing tyrosine kinase activity 
responsible for cytoplasmic phosphorylation of associated members of the HER family. HER2 is encoded by the 
c-erbB-2/neu oncogene, is homologous to HER1 but has no identified ligand. HER3 and HER4 are homologous 
to other members of the HER family. Their extracellular domains are bound by neuregulins (nRGs). The tyrosine 
kinase domain of HER3 exhibits deficient activity. HER4 is boxed and faded because this receptor is probably not 
expressed by epidermal cells, as reported in several independent references.
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only one growth factor activating this receptor22, 
suggesting that each ligand of HER1 may have 
its own effect on development and homeostasis 
of cutaneous tissues. indeed, although all those 
different ligands activate the same receptor, the 
regulation of its activation is not identical. Firstly, 
each ligand seems to activate its own set of HER1 
tyrosine phosphorylation. Secondly, since the sorting 
of ligand-receptor complexes in early endosomes 
depends on potential ligand-receptor dissociation at 
acidic pH, some ligands allow the dissociated EGF 
receptor to recycle, while on the other hand, other 
ligands do not dissociate, leading both the ligand 
and the EGF receptor to degradation.14,23 indicating 
also the involvement of the EGF receptor in skin 
pathology, this receptor was identified as a proto-
oncogene and is suspected of playing some role in 
epidermal cancers: for instance, it is overexpressed 
in certain squamous carcinoma-derived cell lines.3 
Presently, inhibitors of signaling through the EGF 
receptor are under trial as anticancer drugs. Vari-
able successes have been reported to date, probably 
due to variable sensitivity of cancer cells to those 
inhibitors24, but it is also of interest for the scope 
of this review to note that epidermal side-effects 
of those drugs have been reported and indicate 
again that the EGF receptor normally acts in the 
control of epidermal cells25.
interestingly, ligand-independent activation of the 
EGF receptor can be achieved in keratinocytes. For 
figure 2. Dimerization of HERs upon ligand binding triggers cell signaling cascades which may affect keratinocyte 
proliferation, differentiation, or migration. Expression of three members of the HER family in keratinocytes leads 
to the formation of five homo- and/or hetero-dimers upon ligand binding. HER2 has no identified ligand, thus ho-
modimers of HER2 are unlikely to form. Homodimers of HER3 produce no signal. Heterodimers containing HER2 
are preferentially formed when this receptor is present. The cell signaling includes the classical Ras-Mek-MApK 
pathway, pKc, and activation of phosphatidylinositol-3-kinase and Akt. it regulates keratinocyte proliferation, 
differentiation and also migration.
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instance, cholesterol depletion of HaCaT keratino-
cytes26 or of normal keratinocytes27 results in EGF 
receptor activation without the addition of ligand. 
Such activation is followed by a stimulation of the 
expression of heparin-binding EGF-like growth factor 
(HB-EGF)28 and leads to an atypical internalization 
of the EGF receptor29, both phenomena being under 
control of the activity of p38 MApK.
the neU/c-ERBB-2/her-2 oncoGene is eX-
pressed by epiderMal Keratinocytes
The second member of the type 1 family of growth 
factor receptors is a glycoprotein of 185 kDa closely 
related to the EGF receptor. This receptor, identi-
fied first in rat neuroblastomas chemically induced 
by the carcinogen ethylnitrosourea, is the product 
of the neu oncogene whose name was chosen to 
depict its particular neuronal relevance.30 in this 
kind of tumor, a transforming potential of the rat 
glycoprotein was found to result from an oncogenic 
point mutation. However, in the corresponding gene 
subsequently identified in humans, no such precise 
point mutation was ever found. Because of its high 
homology with the EGF receptor, the product of the 
human neu gene was further named c-erbB-2, or 
HER2, although EGF does not bind nor activates this 
receptor.31-33 The HER2 gene product has generated 
a considerable interest in cancer researchers as this 
gene was found overexpressed in some human breast 
and ovarian cancers with poor prognosis.34
normal expression of HER2 in rat and human 
skin, particularly in the epidermis, has been reported 
by several groups studying tissue samples from 
donors of different ages and from various body 
sites.35-37 in the human epidermis, HER2 expres-
sion is up-regulated with keratinocyte differentiation 
and this correlates with the relocalization of the 
protein into the plasma membrane, especially in 
keratinocytes of the granular layer.36,38 in vitro, we 
have demonstrated expression of HER2 in cultures 
of human epidermal keratinocytes and found that 
the HER2 expression is similarly up-regulated when 
cultured cells differentiate.39
The significant expression of the HER2 receptor 
in cutaneous tissues, particularly in the epidermis, 
implies that some role in the regulation of normal 
epidermal cell biology is most probably assigned 
to this molecule. like the EGF receptor, HER2 
exhibits an activable tyrosine kinase cytoplasmic 
domain responsible for signal transduction and 
subsequent regulation of the cellular physiology.14,40 
This property makes normally signaling HER recep-
tors important contributors to normal cell control, 
but also makes them, when deregulated, potentially 
harmful inducers of anarchic cell proliferation. 
However, contrary to what has been described for 
the EGF receptor, no particular overexpression of 
the c-erbB-2 oncogene can be detected in skin 
tumors, including squamous cell carcinomas.36,41 
Thus, despite there being numerous structural ho-
mologies between the EGF receptor and HER2, it is 
suggested that these molecules may have different 
implications in cutaneous physiological processes 
and in malignancies of epidermal origin.
However, during investigations performed on 
the skin of mice that had been treated with the 
tumour-promoting phorbol ester TpA, the following 
observation could be made: tyrosine phosphorylation 
of HER2 is elevated by this kind of treatment, in 
good correlation with the formation of HER2:EGF 
receptor heterodimers.42 These data were completed 
by other studies performed on cultured mouse and 
human keratinocytes: heterodimerization between 
HER2 and the EGF receptor was found after ex-
posure to EGF, together with phosphorylation of 
tyrosine residues.39,42 These results demonstrate 
that ErbB2/HER2 is able to interact with HER1. 
indeed, when this receptor is present, ErbB-2/
HER2-containing HER heterodimers are formed 
preferentially.43 Thus, as in other cell types, the 
presence of HER2 in variable amount available 
for heterodimerization in keratinocyte plasma 
membrane can modulate signal transduction by 
external ligands binding to members of the HER 
family. Furthermore, ligand-independent activation 
through cholesterol depletion of keratinocytes ap-
parently leads also to the formation of heterodimers 
between the EGF receptor and HER2. 
Other studies of the epidermal expression of 
HER2 utilized the production of transgenic mice 
expressing the HER2 under the control of the 
basal keratin 5 promoter.44 The animals reveal 
severe hyperplasia of the follicular and interfol-
licular epidermis, as well as dramatic stimulation 
of keratinocyte proliferation, with appearance of 
papillomas.44 Thus, in cooperation with the EGF 
receptor, HER2 can induce signaling and play a 
previously unexpected role in the control of epi-
dermal cell proliferation.
On the other hand, differences in the normal 
epidermal localization of HER2 and the EGF re-
ceptor argue for potentially different roles in the 
program of epidermal differentiation undergone by 
keratinocytes committed to tissue maintenance and 
19
Folia Medica  LI   (3) July - Sept 2009
renewal.36 Finally, interesting but still poorly un-
derstood findings are the associations of the HER2 
receptor with adhesion molecules: β-catenin and 
plakoglobin45, or the integrin α6β4 involved in the 
basal anchorage through hemidesmosomes.46 As a 
consequence, we may postulate that the activation 
of HER2 might indirectly regulate cellular adhesion 
and/or migration in keratinocytes. in normal cells, 
this type of regulation could be beneficial during 
tissue development and/or repair, however, in car-
cinomas, such a regulation could be disastrous if 
it helps cell dissociation and metastasis.
in the present review, we focus on HER family 
members in the epidermis; however, it must be 
reminded that epidermis is certainly not the tis-
sue where HER2 is mainly involved. Rather, the 
production of mice carrying a null allele of HER2 
has shown the vital importance of this gene in the 
development of the neural system, as well as in 
cardiac development.47 indeed, the embryos carrying 
the null mutation suffer from a markedly affected 
development of cranial sensory ganglia, but also 
from a lacking formation of cardiac trabeculae. This 
absence leads to severe cardiac dysfunctions very 
likely responsible for the embryos death before 
day E11.47 Of course and unfortunately, the inter-
rupted development of HER2 knock-out mice makes 
impossible any evaluation, with such an in vivo 
model, of the role of HER2 in the differentiation 
of mature epidermis and epidermal appendages, but 
to date, no particular abnormality has been reported 
in the developing epidermal tissue.
the c-ERBB-3/her-3 oncoGene is eXpressed 
by epiderMal Keratinocytes
The third member of the HER family of receptors 
was identified later than HER2 by reduced stringency 
hybridization of human genomic dnA.48,49 The so-
called c-erbB-3/HER3 gene also encodes a receptor 
of 180 kDa with typical cytoplasmic tyrosine kinase 
domain. As for the HER2 receptor, it has been 
deduced from hybrid receptors constructed to as-
sociate the extracellular domain of the EGF receptor 
with the cytoplasmic domain of HER3, that ligand 
binding on the extracellular moiety of the receptor 
triggers the tyrosine kinase activity of HER3.50 
However, although other authors have demonstrated 
that the cytoplasmic domain of the receptor has an 
impaired tyrosine kinase activity51, HER3 remains 
an important partner for receptor heterodimerization 
with its numerous docking sites for transduction 
proteins such as pi3K, for example48,49. 
As early as in the first report on HER3, it was 
noticed that this gene is expressed by epidermal cell 
types (keratinocyte and melanocyte). Conversely, 
dermal fibroblasts lack detectable HER3 mRnA.48 
immunohistochemical methods confirmed later the 
localization of this receptor in the epidermis and 
in epidermal appendages.52 As we noted about 
HER2, the expression of HER3 was found also in 
autocrine cultures of human keratinocytes detected 
as the HER3 protein or detected as its encoding 
transcript. An up-regulation of its expression was 
again concomitant with the differentiation process.39 
in vivo, the protein is particularly expressed by the 
differentiated cells of the spinous and granular lay-
ers. These data seriously argue for a regulation of 
epidermal keratinocyte biology by signaling events 
transmitted through the HER3 receptor. nonetheless, 
such a regulation of keratinocytes through HER3 
would not affect the development of the epidermis, 
since it was found that mice with targeted mutations 
in HER3 show no obvious developmental defect in 
epithelia.53 in consequence, we must admit that the 
HER3 receptor may regulate epidermal cells, but 
only after birth, or that other signaling molecules 
compensate during development for a defect in 
this receptor.
interestingly, one initial paper on HER3 also 
reported overexpression of this gene in several hu-
man mammary tumor cell lines48, and analysis of 
its expression in breast cancer later confirmed that 
the transcription of the HER3 gene was upregulated 
in 22% of the cases analyzed in that particular 
study54. More recently, however, the HER3 gene 
has been found expressed at a much higher level 
in normal colon epithelium than in colorectal 
cancers, suggesting that HER3 was not systemati-
cally overexpressed in malignant cell types.55 To 
the best of our knowledge, unfortunately, no pub-
lished study has been specifically devoted so far 
to the analysis of HER3 expression in cutaneous 
malignant tissues.
Recently, forced HER3 expression was found 
able to accelerate the resurfacing of wounds in 
a pig model56, allowing hypotheses that link this 
receptor with healing and growth factors57.
the foUrth MeMber of the her-faMily 
(c-ERBB-4/her-4) is absent froM the sKin
A few years after the discovery of HER3, plowman 
and collaborators identified a fourth member of the 
HER family of receptors which was logically named 
c-erbB-4 or HER4.58 The HER4 receptor exhibits 
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also a molecular weight of 180 kDa and denotes 
highly homologous domains with the three previ-
ously identified members, including a cytoplasmic 
domain with inducible tyrosine kinase activity. The 
expression of HER4 has been reported to be mostly 
neural, but the receptor can also be expressed by 
some breast-derived cancer cell lines. On the other 
hand, the HER4 receptor was not found in the epi-
dermis58, and accordingly, we verified with other 
groups that no transcript for HER4 was detectable 
in either human38,39,59 or mouse42,60 cultured epi-
dermal keratinocytes.
hereGUlins, the her3 and her4 liGand 
faMily, indUce the her2 tyrosine Kinase 
actiVity
Whereas the EGF receptor HER1 had been identi-
fied by its ability to bind a previously identified 
growth factor, EGF itself, the c-erbB/HER2, -3, and 
-4 were initially characterized as orphan receptors 
with no identified ligand, yet these receptors exhibit 
a good homology with the EGF receptor. Thus, the 
members of the increasing family of growth factor 
exhibiting capacity to bind and activate the EGF 
receptor were unable to bind and activate HER2, 
-3 or -4. 
in 1992, two independent groups reported iden-
tification of a factor described as an activator of 
the HER2 receptor as detected by phosphorylation 
of cytoplasmic tyrosine residues on the HER2 (185 
kDa) transmembrane protein. This suggested that 
the factor could be a ligand of HER2.11,12 This 
factor has been originally named by one group neu 
differentiation Factor (ndF) because the isolated 
44 kDa rat protein induces differentiation in a 
breast cancer cell line overexpressing HER2.11,61 
The second group named the factor heregulin to 
refer to its specificity for activation of the HER2 
receptor.12 We will use here the term heregulin to 
designate the ndF/heregulin factor. Heregulin is a 
glycoprotein produced, like similar growth factors, 
as a transmembrane precursor exhibiting, from the 
n-terminal extracellular moiety to the c-terminal 
extremity, an immunoglobulin-like domain, a gly-
cosylated site, an EGF-like domain as well as a 
juxtamembrane and transmembrane domains, and 
a cytoplasmic tail. Several isoforms, have been 
identified and result from alternative splicing of 
transcription products of a common gene. The 
isoforms combine the EGF-like domain alpha or 
beta, one juxtamembranous domain 1, 2, 3 or 4, 
and a cytoplasmic tail identified as a, b or c.12,40,61 
The identity (α or β) of the heregulin EGF-like 
domain, responsible for the ligand-receptor inter-
actions, doesn’t influence the specificity of the 
ligand but define the binding affinity: the affinity 
of β isoforms is ten-fold higher than that of the 
α isoforms.62
Some members of the heregulin family called 
Glial Growth Factor (GGF) or Acetylcholine Recep-
tor inducing Activity (ARiA) have been identified 
as growth factors for glial cells produced by neu-
ronal cells63 or as factors released by presynaptic 
terminals inducing the expression of acetylcholine 
receptors by muscle cells at the neuromuscular 
junction64. Because there is a clear predominance of 
the expression of heregulin by the nervous system65 
and because of the relationship of heregulin with 
HER2, the product of neu oncogene, the factor is 
often referred to as neuregulin.40,63
The critical role in the nervous system of these 
HER2-activating factors has been assessed by the 
production of mice embryos lacking the heregulin 
gene.66 interestingly, these embryos die during de-
velopment and exhibit abnormalities of the neural 
and cardiac systems which mimic abnormalities 
reported in mice lacking the HER2 receptor.47
Recently, three other genes were found related to 
the heregulin gene and their products were named 
neuregulin-267,68, neuregulin-369 and neuregulin-470. 
These new factors signal through HER3 and/or 
HER4 receptors and are apparently not expressed 
in cutaneous tissues.
hereGUlins are eXpressed by epiderMal 
Keratinocytes
Already in the first paper reporting the characteris-
tics of the neu differentiation Factor, it was noted 
that this factor could be expressed in skin tissues.61 
Subsequent studies, using in situ hybridization to 
localize the expression of heregulin in developing 
mice embryos, noticed also that beside predominant 
expression in neural tissues there is a significant 
hybridization of probes over the basal layer of the 
developing skin.65
The expression of heregulin in normal mature 
skin, however, has been studied in rabbits using 
an immunohistochemical approach. in the study, it 
was found that heregulin expression is predomi-
nant in dermal cells, most likely in fibroblasts.71 
looking for heregulin expression in samples of 
superficial normal human skin by RT-pcR detec-
tion of transcripts, we have found a small amount 
of amplified products.39 However, this technique 
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does not allow to distinguish between epidermal 
or dermal origin of the amplified material. north-
ern blot hybridizations of extracts from cultured 
mouse keratinocytes revealed first that these cells 
express small amounts of heregulin transcripts60; 
however, when we performed a similar study on 
samples from cultured human dermal fibroblasts 
and cultured human epidermal keratinocytes, we 
found a much higher expression of heregulins in 
keratinocytes, especially in subconfluent proliferating 
cells, than in fibroblasts39. The level of heregulin 
transcripts detected in rapidly dividing keratinocytes 
was so high that it did overcome the level found 
in MdA-231 cells, the human breast cancer cell 
line utilized for the initial isolation of heregulin.12 
Such high expression is detected in subconfluent 
cultures of human keratinocytes, but drastically 
decreases when the cells become confluent and 
initiate the expression of early markers of epider-
mal differentiation.19,39 In vivo, the expression of 
heregulin is also down-regulated by differentiation. 
To our knowledge, no such regulation of heregu-
lin expression depending on culture conditions of 
a normal cell type has been previously reported. 
Therefore, cultures of keratinocytes could be of 
special interest to study the basic regulation of 
heregulin expression.
hereGUlin siGnals throUGh receptor 
heterodiMers.
Relative binding affinities of different growth fac-
tors of the EGF family measured on soluble recep-
tors72 have demonstrated that we may discriminate 
between three types of ligands. A few growth fac-
tors like EGF, TGF-α and amphiregulin(AR) bind 
only to HER1. Betacellulin (BC), Heparin binding 
(HB)-EGF and epiregulin bind to HER1 but also to 
HER4. Heregulins bind only to HER3 and HER4. 
HER2 remains an orphan receptor but is thought 
to play a crucial role as a preferential partner for 
heterodimerization between HER family members. 
indeed, despite a first line of evidence suggested 
that incubations of certain cell lines with heregulins 
resulted in signal transduction through the HER2 
receptor, it was rapidly recognized though that the 
interactions between heregulins and members of 
the EGF receptor family could be more complex.73 
indeed, more evidence followed, suggesting that 
co-expression of the HER2 receptor with the HER4 
receptor, or alternatively of the HER2 receptor with 
the HER3 receptor, was required to obtain activa-
tion of the HER2 molecule by heregulins.74,75 The 
particular importance of this heterodimerization 
process for signaling through heregulins and HER2 
has been recently demonstrated: mice embryos were 
produced that lacked the HER4 receptor and these 
embryos died in utero, between E10 and E11. At 
that time of embryogenesis, HER4-null mice were 
shown to suffer exactly like HER2-null mice or 
heregulin-null mice from aberrant neural and cardiac 
development.47,66,76 
in epithelial cells, and particularly in the epi-
dermis where keratinocytes do not express HER4, 
HER3 and its impaired tyrosine kinase activity 
heterodimerizes with HER2 to constitute the pre-
dominant form of heregulin receptor.39,77 
hereGUlins with her2 and her3 consti-
tUte a potential paracrine systeM in 
epiderMis.
The variations of the expression of the different 
HER family members and of heregulin in normal 
human keratinocytes undergoing normal epidermal 
differentiation, as described above, suggest that 
these molecules may constitute an intraepidermal 
paracrine system in which proliferating cells express 
amounts of a growth factor which act mainly on 
differentiating cells (Fig. 3). it seems, therefore, 
reasonable to speculate potential involvement of 
heregulins and their complex receptor system in 
later skin development (i.e. after E11 in mouse), in 
normal homeostasis of epidermal layers and/or in 
tissue repair during cutaneous wound healing. Prob-
ably, the most straightforward experimentation to 
evaluate the role of an identified gene is to produce 
knock-out mice for this particular gene. Unfortu-
nately, the role of heregulins and their receptors in 
mature cutaneous cell signaling in vivo cannot be 
studied with null mice since these embryos lack-
ing heregulin die in utero before birth, due to the 
cardiac anomalies also observed in embryos lacking 
HER2 or HER3.47,66,76
interestingly, the expression of HER2 and HER3 
is regulated in cultured human keratinocytes in 
accordance with in vivo data, being minimal in 
subconfluent rapidly growing cultures but being 
increased several times when the cells become 
confluent and initiate terminal differentiation.39 
Thus, treatment of cultures of human epidermal 
keratinocytes with heregulin isoforms induces HER2 
activation (tyrosine phosphorylation) in confluent 
culture conditions only. Accordingly, we have not 
been able to show any effect of heregulin treat-
22
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figure 3. localization of HER-dependent signaling in keratinocytes embedded in a normal epidermis. Keratino-
cytes produce ligands for HER1 (TGF-α, Hb-EGF, Amphiregulin), as well as neuregulins (nRGs). neuregulins 
are mainly produced by basal keratinocytes producing a gradient represented by the red triangle, whereas HER3 
is mainly expressed by suprabasal keratinocytes, producing an inverted gradient of the receptors (blue triangle). 
HER2 is also upregulated in differentiating keratinocytes. Heterodimers including HER2 induce the most potent 
signaling in suprabasal layers. HER2 produced in proliferating keratinocytes is mostly intracellular and relocated 
into the plasma membrane of differentiating keratinocytes of the upper spinous and granular cell layers38, while 
HER2 expressed in basal keratinocytes is associated with the integrin α6β4, possibly regulating migratory prop-
erties of cells46.
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ment on subconfluent keratinocytes, whereas a 
significant suppression of the expression of markers 
of epidermal differentiation was produced by this 
treatment.39 This effect of an activation of HER2 
in keratinocytes is similar to the effect produced 
when these cells are incubated with EGF in order 
to activate HER1.19
According to data available in the literature, such 
a regulation of HER3 expression in a normal cell 
type is unique so far to the human keratinocyte 
culture system. Therefore, culture of keratinocytes 
could be of value to study the normal control of 
HER3 expression. 
Finally, we have to mention that apparently the 
responsiveness of mouse keratinocytes to heregu-
lins60 differs from the responsiveness of human 
keratinocytes39, most probably as a consequence of 
the yet unexplained different regulation of HER3 
expression in mouse epidermal cells.
possible inVolVeMent of her2 in cUtane-
oUs patholoGies
The HER2 proto-oncogene seems to be critical in 
certain mammary and ovarian cancers where over-
expression of this receptor is detected. Thereby, 
HER2 is an interesting target for immunotherapy of 
these cancers.77,78 Since HER2 is not over-expressed 
in squamous cell carcinomas, no unusual signaling 
through this receptor during this kind of tumoral 
development can be hypothesized. On the other 
hand, our findings about heregulin production by 
epidermal keratinocytes and the requirement for 
HER2 and HER3 heterodimerization in order to 
signal in these cells39,60 indicate future investiga-
tions that should identify whether this system of 
ligands and receptors is involved in the etiology 
of epidermal tumors. nevertheless, HER2 has been 
shown to partially induce a malignant phenotype in 
papilloma-derived keratinocytes, but the effect pro-
duced through HER2 was reported as less potent than 
the induction obtained with the ras oncogene.79
in some human dermal naevi and cutaneous mela-
nomas, the HER2 receptor is apparently expressed, 
but at a level lower than in normal keratinocytes.80,81 
Also, when the expression of HER2 was measured 
at mRnA level in psoriatic epidermis and com-
pared with the same expression in normal tissue, 
no significant difference was found.82 On the other 
hand, over-expression has been interestingly reported 
in human radiation-induced skin ulcers83 and the 
involvement of HER2 could thereby be suspected 
in the cancer transformation and poor healing of 
these particular radiation-induced skin lesions. More 
recent results obtained with transgenic mice further 
support this hypothesis.44 in these mice, HER2, 
under the control of the bovine keratin 5 promoter, 
is overexpressed in keratinocytes of the epidermal 
basal layer resulting in a significant epidermis 
hyperplasia, a dramatic increase in keratinocyte 
proliferation and the development of a squamous 
cell carcinoma-like appearance.
Finally, due to the epidermal localization of 
the abnormal cells observed in mammary Paget’s 
disease, the studies reporting the expression of 
HER2 in such cases have to be mentioned here.83,84 
particularly, the localization of the HER2 receptor 
at tumor cell membranes was noticed in Paget’s 
disease.85,86 in order to explain the pathogenesis of 
this disease, an interesting hypothesis, proposing 
that epidermal keratinocytes may release chemot-
actic factors attracting in the epidermis carcinoma 
cells over-expressing HER2, has been tested. Such 
a putative motility factor, which probably acts as a 
ligand with specificity for HER2, has indeed been 
detected during in vitro investigations.86 Recently, 
it was demonstrated that HRGα could be a potent 
chemoattractant protein eventually implicated in 
the Paget's disease.87
perspectiVes
in this review, we have focused our attention on 
the existence of an intraepidermal system in which 
heregulin is expressed by proliferating keratinocyte 
and may activate, by a paracrine loop, the differenti-
ated keratinocytes of the suprabasal layers (Fig. 3). 
in this model, heregulin may also activate, by an 
autocrine loop, the weakly expressing HER2 and 
HER3 keratinocytes of the basal layer. We may 
postulate that this system is implicated in normal 
homeostasis of epidermal layers and/or in tissue 
repair during cutaneous wound healing. nonethe-
less, studying the role of heregulin-HER receptor 
system in the control of the keratinocyte physiology 
remains a real challenge for the future.
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Представители EGF- рецеПторной 
фамилии в нормальном и Патоло-
гическом эПидермисе
Ив Пуме, В. Митев
резюме
Эпидермальный фактор роста (EGF) и его 
аналоги связываются с трансмембранными 
рецепторами EGF рецепторной фамилии, обла-
дающими тирозин-киназной активностью в своем 
цитоплазманическом домене. Эти факторы роста 
и их соответствующие рецепторы получили свои 
наименования после первоначального установления 
их функций в эпидермисе. После доказывания 
действия EGF-рецептора как онкоген его ши-
роко исследовали в случаях наличия опухоли. Ус-
тановлены и другие члены той же фамилии, 
которых охарактеризовали и анализировали в 
доброкачественных и злокачественных опухолевых 
клетках. В настоящем обзоре преимущественно 
рассматриваются функции EGF рецепторной семьи 
в нормальном эпидермисе одновременно с экспрессией 
и ролью их соответствующих лиганд. Обсуждается 
и потенциальное участие этих молекул в различных 
заболеваниях эпидермиса.
